Status:

COMPLETED

A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)

Lead Sponsor:

Targacept Inc.

Conditions:

Age-Related Memory Disorders

Eligibility:

All Genders

50-80 years

Phase:

PHASE2

Brief Summary

The purpose of this Phase II study is to evaluate the efficacy and safety of ispronicline (TC-1734-112) compared to placebo (inactive substance pill) in patients with age associated memory impairment ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Male or female subjects aged 50-80 years.
  • Lives with a significant other.
  • Has subjective memory complaints. Verbal verification of this subjective memory complaint will be obtained from the significant other.
  • Has no severe, uncontrolled medical condition.
  • If receiving treatment for a medical condition, that treatment has been stable for at least 2 months before entering the trial and to remain stable throughout the trial.
  • Exclusion Criteria
  • Aged less than 50 years or greater than 80 years.
  • Lives alone.
  • Has any medical condition not adequately controlled, or likely to interfere with performance of the study procedures.
  • Medication for a medical condition has been changed in the last 2 months or during the trial.
  • Administration of acetylcholinesterase inhibitors and gingko biloba within 2 months prior to entering the study.
  • Has evidence of depression or anxiety
  • Meets DSM-IV criteria for Alzheimer's or vascular dementia.
  • Has participated in an investigational drug trial in the previous 30 days.

Exclusion

    Key Trial Info

    Start Date :

    January 1 2005

    Trial Type :

    INTERVENTIONAL

    End Date :

    October 1 2005

    Estimated Enrollment :

    174 Patients enrolled

    Trial Details

    Trial ID

    NCT00109564

    Start Date

    January 1 2005

    End Date

    October 1 2005

    Last Update

    July 18 2008

    Active Locations (15)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 4 (15 locations)

    1

    Pivotal Research Center

    Mesa, Arizona, United States, 85210

    2

    Pivotal Research Center

    Peoria, Arizona, United States, 85381

    3

    Radiant Research

    Denver, Colorado, United States, 80212

    4

    Neuropsychiatric Research Center of SW Florida

    Fort Meyers, Florida, United States, 33912

    A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI) | DecenTrialz